Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis.

Andela VB, Rosenblatt JD, Schwarz EM, Puzas EJ, O'Keefe RJ, Rosier RN.

Clin Orthop Relat Res. 2002 Apr;(397):228-39.

PMID:
11953614
2.

Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.

Cancer Res. 2001 Dec 15;61(24):8758-68.

3.

The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.

Caraglia M, D'Alessandro AM, Marra M, Giuberti G, Vitale G, Viscomi C, Colao A, Prete SD, Tagliaferri P, Tassone P, Budillon A, Venuta S, Abbruzzese A.

Oncogene. 2004 Sep 9;23(41):6900-13.

PMID:
15286715
4.

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C.

Cancer Res. 2001 Jan 1;61(1):131-7.

5.

Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.

Le Gouill S, Pellat-Deceunynck C, Harousseau JL, Rapp MJ, Robillard N, Bataille R, Amiot M.

Leukemia. 2002 Sep;16(9):1664-7.

6.

Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.

Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End D, Howes AJ, Dowsett M, Workman P, Johnston SR.

Clin Cancer Res. 2001 Nov;7(11):3544-50.

7.

The mevalonate synthesis pathway as a therapeutic target in cancer.

Andela VB, Pirri M, Schwarz EM, Puzas EJ, O'Keefe RJ, Rosenblatt JD, Rosier RN.

Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S59-66. Review.

PMID:
14600593
8.

Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel.

Nakamura K, Yamaguchi A, Namiki M, Ishihara H, Nagasu T, Kowalczyk JJ, Garcia AM, Lewis MD, Yoshimatsu K.

Oncol Res. 2001;12(11-12):477-84.

PMID:
11939411
9.

Farnesyl transferase inhibitors in the treatment of breast cancer.

Kelland LR.

Expert Opin Investig Drugs. 2003 Mar;12(3):413-21. Review.

PMID:
12605564
10.
11.

Protein prenyl transferase activities of Plasmodium falciparum.

Chakrabarti D, Azam T, DelVecchio C, Qiu L, Park YI, Allen CM.

Mol Biochem Parasitol. 1998 Aug 1;94(2):175-84.

PMID:
9747968
12.

Farnesyl transferase inhibitors as anticancer agents.

Haluska P, Dy GK, Adjei AA.

Eur J Cancer. 2002 Sep;38(13):1685-700. Review.

PMID:
12175684
13.
14.

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J.

Blood. 2001 Jun 1;97(11):3361-9.

15.

Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis.

Liesveld JL, Lancet JE, Rosell KE, Menon A, Lu C, McNair C, Abboud CN, Rosenblatt JD.

Leukemia. 2003 Sep;17(9):1806-12.

PMID:
12970780
16.

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.

Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G.

Arch Biochem Biophys. 2000 Jan 1;373(1):231-41.

PMID:
10620343
17.
18.

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.

Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, Talpaz M, Kantarjian H.

Blood. 2003 Mar 1;101(5):1692-7. Epub 2002 Oct 31.

19.

Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.

Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Li Z, Dell J, Lipari P, Malkowski M, Prioli N, Rossman RR, Korfmacher WA, Nomeir AA, Lin CC, Mallams AK, Doll RJ, Catino JJ, Girijavallabhan VM, Kirschmeier P, Bishop WR.

Cancer Chemother Pharmacol. 1999;43(1):50-8.

PMID:
9923541
20.

Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.

Karp JE.

Semin Hematol. 2001 Jul;38(3 Suppl 7):16-23. Review.

PMID:
11523024

Supplemental Content

Support Center